On July 21, 2020 Acentrus Specialty, a national network of health systems and hospitals committed to providing specialty pharmacy care for their patients, reported that it has finalized an agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) to provide qualified Acentrus clients access to NERLYNX (neratinib) (Press release, Acentrus Specialty, JUL 21, 2020, View Source [SID1234562203]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to provide our network hospitals and their patients access to an important breast cancer treatment"
"We are pleased to provide our network hospitals and their patients access to an important breast cancer treatment," said Acentrus Specialty Vice President George Zula. "Limited distribution drugs like NERLYNX are highly sought after but can be difficult to obtain. Acentrus works with drug companies to open the door to these medications for specialty pharmacies operated by our network hospitals. This means that patients can begin potentially life-saving treatments sooner and with the significant advantage of integrated care from pharmacy professionals they know and trust."
Participation in Acentrus is open to hospital organizations of all sizes, types and affiliations. Clients, which range from academic medical centers to community-based hospitals, share one goal: to provide their patients with high-quality care in a setting where clinical and pharmacy services are integrated.
There is no cost for an organization to join the Acentrus network, which provides more than 100 health systems and hospitals with the following benefits:
Access to difficult-to-obtain specialty medications
Data management
Collaboration with health system peers dedicated to sharing best practices
Portfolio of other services to help hospital-based specialty pharmacies meet the needs of their patients, including backup and contract pharmacy as well as expertise in licensing and accreditation
Specialty medications represent the fastest growth sector in pharmacy, with 1-2% of all claims accounting for 50-60% of all expenses. Specialty pharmaceuticals are typically limited distribution drugs (LDDs) available only to certain providers through exclusive networks established by manufacturers.